Table 1.
Results of the Use of Alfuzosin, Sildenafil, or a Combination of Both on Lower Urinary Tract Symptoms and Erectile Dysfunction Measures
| Alfuzosin | Alfuzosin | Sildenafil | Sildenafil | Combination | Combination | |
|---|---|---|---|---|---|---|
| Baseline | at 12 | Baseline | at 12 | Baseline | at 12 | |
| (n = 20) | Weeks | (n = 21) | Weeks | (n = 21) | Weeks | |
| IPSS | 17.3 | 14.6 | 17.8 | 14.9 | 17.3 | 13.5 |
| Qmax (mL/s) | 9.4 | 10.5 | 9.7 | 10.3 | 9.5 | 11.5 |
| PVR (mL) | 54 | 31 | 46 | 34 | 53 | 32 |
| Frequency (voids/day) | 8.7 | 6.4 | 9.1 | 7.8 | 9.3 | 6.1 |
| Nocturia (voids/night) | 2.9 | 1.8 | 2.6 | 2.1 | 3.1 | 1.8 |
| IIEF | 17.4 | 20.3 | 14.3 | 21.4 | 16.2 | 25.7 |
IPSS, International Prostate Symptom Score; Qmax, peak urinary flow rate; PVR, postvoid residual urine; IIEF, International Index of Erectile Function. Reproduced from Kaplan SA et al,19 with permission from the American Urological Association.